



Press Release July 1<sup>st</sup>, 2008

## Successful quarter for Diamyd

*Elisabeth Lindner, President and CEO of Diamyd Medical, communicates in the CEO overview in the quarterly report published today, that the last quarter has been both successful and of vital importance to the development of the company.*

Phase III studies have been approved and initiated in Sweden and the US, and approvals are expected from a number of European countries in August and September. Inclusion of patients is ongoing in Sweden and ethics approvals for participating US sites have started to come in.

A successful direct placement was accomplished and warrants have been listed for trading.

To date, all pursued and planned clinical trials with Diamyd<sup>®</sup> concern patients diagnosed with type 1 diabetes or LADA. The Chairman of **TrialNet**, Professor **Jay Skyler**, communicated during the ADA conference in San Francisco on 9<sup>th</sup> of June, that in addition to the planned intervention study with 126 patients, a prevention study with Diamyd<sup>®</sup> in healthy individuals at risk to develop type 1 diabetes is planned.

- Diamyd Medical has experienced a fantastic quarter, says President and CEO **Elisabeth Lindner**. We have, as a fairly small research company, in a very short period of time, succeeded to move our Phase III studies into a phase where we are actively including patients. Furthermore, there is interest from TrialNet to study whether Diamyd<sup>®</sup> can *prevent* type 1 diabetes. Should Diamyd<sup>®</sup> not only improve the situation for children, that already have diabetes, but also prevent the disease, this would be a dramatic break-through. Finally, our financial position is strengthened after a fully subscribed direct issue of new shares. It is with great pleasure that I am publishing this quarterly report, concludes President and CEO Elisabeth Lindner.

**For more information, please contact:**

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.), [elisabeth.lindner@diamyd.com](mailto:elisabeth.lindner@diamyd.com)  
Phone: +46-8-661 0026

**For pictures and press material, please contact:**

Sonja Catani, Chief Communications Officer Diamyd Medical AB, [sonja.catani@diamyd.com](mailto:sonja.catani@diamyd.com)  
Phone: +46-8-661 00 26

*This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.*

*Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd<sup>®</sup> for type 1 diabetes and for which Phase III trials have been initiated in both the US and Europe. Furthermore the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.*

*Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site: [www.diamyd.com](http://www.diamyd.com)*

**Diamyd Medical AB (publ.)**

Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8 661 63 68

E-post: [info@diamyd.com](mailto:info@diamyd.com). VATno: SE556530-142001.